• GROWING: AMAG is focused on driving organic growth of its products in their indicated patient populations.

  • BUILDING: AMAG intends to expand its portfolio with additional commercial-stage specialty products that leverage the company’s strong foundation.

  • TOGETHER: We will develop and build AMAG’s organizational capabilities to support our planned growth and expansion.

AMAG is a rapidly growing, specialty pharmaceutical company, supported by a talented and passionate workforce. Our primary goal is to bring to market therapies that provide clear benefits and improve patients’ lives.

AMAG announces the appointment of Melissa Klug as senior vice president of business development and strategy.  Ms. Klug has more than 15 years of hands-on strategic planning, licensing, and business development experience in the life sciences industry.  She has executed multiple business development transactions and established key financial metrics to support investments or acquisitions of new technologies, assets and companies, including the acquisition of CNS Therapeutics and two Phase III assets that formed the foundation for a pain franchise and generated more than $250 million in revenue annually.

 

AMAG Pharmaceuticals is proud to be awarded #59 in the 2013 Deloitte Technology Fast 500™, which recognizes the fastest-growing technology, media, telecommunications, life sciences and clean technology companies in North America.

 

AMAG currently markets an intravenous iron for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) in the United States.

LEARN MORE

AMAG currently markets an oral rinse for the management of oral mucositis in the United States.

LEARN MORE

AMAG recently launched Iron Matters™ to help educate patients about iron deficiency anemia (IDA).

READ MORE

AMAG employees participate in the World Kidney Day celebration by starting the day with a drink of water.  The mission of World Kidney Day is to raise awareness of the importance of our kidneys to our overall health and to reduce the frequency and impact of kidney disease and its associated health problems worldwide.